undamentalytics Newsletter
Sign in

Enovis Corp (ENOV) stock

Add to watchlist

Add holding +

NYSE: ENOV NYSE Health Care Equipment Next results ~November 5, 2026

C Fundamentals grade

Enovis Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$52

Valuation models combined (3)

Base case. Range ~$41–$61. Weighted average of 3 models (forward price-to-earnings vs peers, forward price-to-sales vs peers, revenue-to-maturity model).

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Enovis Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 1 selling18 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds127 adding, 132 cuttingOf 48 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Enovis files

Where Enovis stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $2.30bn, up 4.9% on a year earlier, slower than the 6.0% growth a quarter earlier. Free-cash-flow margin rose to 2.8% from -0.2% a year earlier. Operating margin narrowed to -45.1% from -34.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 7 financial-health checks. Our valuation models combined value is $54.91 a share, against a share price of $21.23.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Enovis Corp's trailing-twelve-month revenue grew 4.9% year on year, with a free-cash-flow margin of 2.8%. Where it stands out: stock pay as % of revenue of 1.5% ranks 22 of 123 health care equipment companies we cover.

Current signal Gross margin expanding: TTM gross margin reached 61.1%, up 3.5pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -45.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 10.4 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 65% and a beta of 1.4 against the S&P 500.
  • Heavily shorted. 24.2% of the shares available to trade are sold short (7.1 days of average volume to cover).
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 13.2% over 90 days.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.90 against an average estimate of $0.85: beat by 6.3%
Revenue
$583m, up 3.2% on a year earlier
Share reaction
-11.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
revenue $2.31bn to $2.37bn (2026); organic revenue growth growth 4% to 6% (2026)
Next report
November 5, 2026; average EPS estimate $0.77

Enovis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.6%
  • 1 week-2.6%
  • 1 month+16.0%
  • This year-22.6%
  • 1 year-34.0%
  • 5 years-77.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.3B
Operating margin
-45.1%
Net margin
-48.0%
EPS (TTM, diluted)
$-19.22

Growth

Revenue growth
+4.9%
Change in growth rate
−1.1 pts
Share count change
+1.7%

Cash

Free cash flow (TTM)
$63.7M
FCF margin
2.8%
Stock pay % of revenue
1.5%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Enovis Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Enovis Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$61 ~$52–$94 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$53 ~$59–$200 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$41 ~$28–$56 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$52 ~$41–$61 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Enovis Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$40.19$61.84$68.19$35.97$62.62$65.82$79.12$53.52$56.02$43.88$26.64$20.62
Market value$1.7bn$2.5bn$2.8bn$1.4bn$2.9bn$3.0bn$4.0bn$2.9bn$3.1bn$2.4bn$1.5bn$1.2bn
+ Net debt (− = net cash)$1.2bn$1.1bn$808m$1.1bn$2.2bn$2.1bn$1.4bn$235m$444m$1.3bn$1.3bn$1.3bn
Enterprise value$2.9bn$3.6bn$3.6bn$2.6bn$5.1bn$5.2bn$5.5bn$3.1bn$3.5bn$3.7bn$2.8bn$2.5bn
Multiples
Price / sales 0.5x0.8x1.5x0.7x0.9x2.7x2.8x1.9x1.8x1.2x0.7x0.5x
Price / earnings 10.0x19.8x18.7x10.3x—70.4x56.5x—————
Price / free cash flow 7.2x13.8x18.8x9.2xn/m16.0x16.1x—n/m—76.3x18.6x
EV / EBITDA 7.2x9.9x17.4x11.1x12.1x50.6x44.0x23.7x23.1x24.5x12.7x7.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

48 /100

Moderate moat

How hard Enovis's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 3 / 20

    Cash operating profit has been a median 4.2% of total assets over 10 years.

  • Pricing power 6 / 20

    Gross margin has been a median 39.7%, moving by 12.6 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -1.9%; its worst year was -45.1%.

  • Cash conversion 8 / 20

    Free cash flow was positive in 7 of 10 years, at a median 2.8% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 58.6% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $557m and EPS of $0.77 (range $0.71 to $0.83) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.63 +10% $2.3bn +4%
Next $3.54 −2% $2.5bn +5%

Next year's EPS estimate has moved −13.2% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.4% on 90 days ago. In the last 30 days, 0 analysts raised Enovis Corp's forecast and 2 cut it.

Consensus EPS forecast Enovis Corp, last 90 days
$3.40 $3.60 $3.80 $4.00 $4.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $3.64 Current fiscal year, 60 days ago: $3.64 Current fiscal year, 30 days ago: $3.64 Current fiscal year, 7 days ago: $3.63 Current fiscal year, Now: $3.63 $3.63 Next fiscal year, 90 days ago: $4.08 Next fiscal year, 60 days ago: $4.01 Next fiscal year, 30 days ago: $3.69 Next fiscal year, 7 days ago: $3.54 Next fiscal year, Now: $3.54 $3.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $3.64$4.08
60 days ago $3.64$4.01
30 days ago $3.64$3.69
7 days ago $3.63$3.54
Now $3.63$3.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.85 $0.90 +6.3%
Mar 2026 $0.81 $0.89 +9.9%
Dec 2025 $0.84 $0.95 +13.1%
Sept 2025 $0.65 $0.75 +15.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • Revenue 2026 $2.31bn to $2.37bn Maintained
    “Revenue is expected to be in a range of $2.31-2.37 billion, which incorporates 4-6% organic revenue growth.” source
  • Adjusted earnings per share full-year 2026 $3.52 to $3.73 Non-GAAP Maintained
    “Full-year adjusted earnings per share is expected to be in a range of $3.52 to $3.73.” source
  • Organic revenue growth 2026 4% growth to 6% growth Maintained
    “Revenue is expected to be in a range of $2.31-2.37 billion, which incorporates 4-6% organic revenue growth.” source
  • Adjusted EBITDA 2026 $425m to $435m Non-GAAP Maintained
    “Adjusted EBITDA is expected to be in a range of $425-435 million.” source
  • Free cash flow conversion full year 2026 about 25% Non-GAAP Maintained
    “Full year free cash flow conversion is expected to be 25% or higher.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

13 analysts, Nov 2026
Buy1292%
Hold18%
Sell00%

Monthly trend

  1. Nov 2026210113
  2. Oct 2026210113
  3. Sep 2026210113

Counts of recommendations published by analysts covering Enovis Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
24.2%
of tradable shares
Days to cover
7.14
at average volume
Short interest, 1 month
+23%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.6%
of shares
Employees
7,802
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −34.0%

$31.24 on October 31, 2025 to $20.62

ThenNowEffect
Revenue (last 12 months) $2.2bn $2.3bn +4.9%
P/S multiple 0.8x 0.5x −36.0%
Share count 56m 57m −1.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −56.1%

$47.02 on November 3, 2023 to $20.62

ThenNowEffect
Revenue (last 12 months) $1.6bn $2.3bn +41.1%
P/S multiple 1.6x 0.5x −67.1%
Share count 54m 57m −5.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ENOV+20%−32%+5%−22%−39%−23%
Industry peers (median)−9%−37%−9%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ENOV50%33%42%42%33%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ENOV−19%−45%−34%−39%−46%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 81% from November 5, 2021 to October 8, 2026. Getting back needed a 423% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$17.43 – $31.51
From 52-week high
−34.6%
vs 50-day average
+3.6%
vs 200-day average
−10.6%
Volatility (1 year)
65%
Beta vs S&P 500
1.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±8.1%
After a week
7 up, 5 down
typical move ±7.1%
After a month
4 up, 8 down
typical move ±10.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −11.8% +0.5% −15.0% −38.5%
May 7, 2026 +6.7% +0.5% +5.1% −4.7%
February 26, 2026 +14.1% −1.0% +9.0% −2.2%
November 6, 2025 −10.9% −1.0% −2.0% −15.0%
August 7, 2025 +10.4% +0.7% +11.9% +21.9%
May 8, 2025 −3.5% +0.6% +4.4% −3.9%
February 26, 2025 −9.5% −1.5% −10.7% −7.6%
November 6, 2024 +10.5% +3.3% +7.3% +10.0%
August 7, 2024 +3.8% +1.6% +2.5% +3.5%
May 2, 2024 −7.5% +2.2% −7.9% −11.3%
February 22, 2024 +4.3% +2.1% −0.8% −0.1%
November 7, 2023 +4.0% +0.4% +8.4% +8.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Enovis Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Enovis Corp
$1.6B $1.8B $2B $2.2B $2.4B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.7B Revenue (TTM), FY23 Q4: $1.7B Revenue (TTM), FY24 Q1: $1.8B Revenue (TTM), FY24 Q2: $1.9B Revenue (TTM), FY24 Q3: $2B Revenue (TTM), FY24 Q4: $2.1B Revenue (TTM), FY25 Q1: $2.2B Revenue (TTM), FY25 Q2: $2.2B Revenue (TTM), FY25 Q3: $2.2B Revenue (TTM), FY25 Q4: $2.2B Revenue (TTM), FY26 Q1: $2.3B Revenue (TTM), FY26 Q2: $2.3B $2.3B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.7B
FY23 Q4 $1.7B
FY24 Q1 $1.8B
FY24 Q2 $1.9B
FY24 Q3 $2B
FY24 Q4 $2.1B
FY25 Q1 $2.2B
FY25 Q2 $2.2B
FY25 Q3 $2.2B
FY25 Q4 $2.2B
FY26 Q1 $2.3B
FY26 Q2 $2.3B
Revenue growth, TTM YoY Enovis Corp
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -24.6% Revenue growth, TTM YoY, FY23 Q4: -22.8% Revenue growth, TTM YoY, FY24 Q1: 14.0% Revenue growth, TTM YoY, FY24 Q2: 17.6% Revenue growth, TTM YoY, FY24 Q3: 20.5% Revenue growth, TTM YoY, FY24 Q4: 23.5% Revenue growth, TTM YoY, FY25 Q1: 18.3% Revenue growth, TTM YoY, FY25 Q2: 14.4% Revenue growth, TTM YoY, FY25 Q3: 11.6% Revenue growth, TTM YoY, FY25 Q4: 6.7% Revenue growth, TTM YoY, FY26 Q1: 6.0% Revenue growth, TTM YoY, FY26 Q2: 4.9% 4.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -24.6%
FY23 Q4 -22.8%
FY24 Q1 14.0%
FY24 Q2 17.6%
FY24 Q3 20.5%
FY24 Q4 23.5%
FY25 Q1 18.3%
FY25 Q2 14.4%
FY25 Q3 11.6%
FY25 Q4 6.7%
FY26 Q1 6.0%
FY26 Q2 4.9%
Operating margin (TTM) Enovis Corp
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -5.3% Operating margin (TTM), FY23 Q4: -3.8% Operating margin (TTM), FY24 Q1: -4.2% Operating margin (TTM), FY24 Q2: -5.5% Operating margin (TTM), FY24 Q3: -5.8% Operating margin (TTM), FY24 Q4: -36.8% Operating margin (TTM), FY25 Q1: -36.6% Operating margin (TTM), FY25 Q2: -34.7% Operating margin (TTM), FY25 Q3: -57.6% Operating margin (TTM), FY25 Q4: -50.0% Operating margin (TTM), FY26 Q1: -47.0% Operating margin (TTM), FY26 Q2: -45.1% -45.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -5.3%
FY23 Q4 -3.8%
FY24 Q1 -4.2%
FY24 Q2 -5.5%
FY24 Q3 -5.8%
FY24 Q4 -36.8%
FY25 Q1 -36.6%
FY25 Q2 -34.7%
FY25 Q3 -57.6%
FY25 Q4 -50.0%
FY26 Q1 -47.0%
FY26 Q2 -45.1%
FCF margin (TTM) Enovis Corp
-10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -6.0% FCF margin (TTM), FY23 Q4: 0.7% FCF margin (TTM), FY24 Q1: -2.1% FCF margin (TTM), FY24 Q2: -3.1% FCF margin (TTM), FY24 Q3: -3.1% FCF margin (TTM), FY24 Q4: -3.2% FCF margin (TTM), FY25 Q1: -1.8% FCF margin (TTM), FY25 Q2: -0.2% FCF margin (TTM), FY25 Q3: 1.0% FCF margin (TTM), FY25 Q4: 0.9% FCF margin (TTM), FY26 Q1: 1.6% FCF margin (TTM), FY26 Q2: 2.8% 2.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -6.0%
FY23 Q4 0.7%
FY24 Q1 -2.1%
FY24 Q2 -3.1%
FY24 Q3 -3.1%
FY24 Q4 -3.2%
FY25 Q1 -1.8%
FY25 Q2 -0.2%
FY25 Q3 1.0%
FY25 Q4 0.9%
FY26 Q1 1.6%
FY26 Q2 2.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jul 2026
Income
Revenue 525 542 693 3,914 4,207 4,624 3,434 3,186 1,937 2,193 3,327 1,121 1,426 1,563 1,707 2,108 2,248 2,297
Gross profit 186 191 240 1,152 1,306 1,479 1,072 992 672 729 1,401 604 778 869 991 1,181 1,345 1,403
EBITDA — 51 49 323 526 584 403 366 208 233 419 102 124 132 151 152 220 309
Operating income 40 34 26 140 406 410 266 237 136 152 204 −66 −63 −71 −66 −776 −1,124 −1,037
Net income 24 16 5 −64 179 392 168 128 151 140 −528 43 72 −13 −33 −825 −1,184 −1,102
Diluted EPS $0.82 $0.56 $0.15 −$2.76 $4.62 $9.06 $4.02 $3.12 $3.66 $3.48 −$11.67 $0.93 $1.40 −$0.25 −$0.61 −$14.93 −$20.75 −$19.22
Growth (year on year)
Revenue — +3.2% +27.9% +464.5% +7.5% +9.9% −25.7% −7.2% −39.2% +13.2% +51.7% −66.3% +27.3% +9.6% +9.2% +23.5% +6.7% +4.9%
EBITDA — — −5.2% +566.8% +62.5% +11.2% −31.1% −9.2% −43.0% +11.7% +80.1% −75.7% +22.1% +6.1% +14.9% +0.5% +44.6% +80.0%
Operating income — −13.3% −24.6% +440.5% +190.3% +0.8% −35.1% −10.8% −42.7% +11.8% +34.4% −132.5% — — — — — —
Net income — −31.9% −71.9% — — +119.5% −57.2% −23.6% +17.9% −7.2% −476.4% — +68.1% −118.5% — — — —
Diluted EPS — −32.7% −73.0% — — +96.1% −55.6% −22.4% +17.3% −4.9% −435.3% — +50.5% −117.9% — — — —
Margins
Gross margin 35.4% 35.3% 34.6% 29.4% 31.0% 32.0% 31.2% 31.2% 34.7% 33.3% 42.1% 53.9% 54.5% 55.6% 58.0% 56.0% 59.8% 61.1%
EBITDA margin — 9.4% 7.0% 8.3% 12.5% 12.6% 11.7% 11.5% 10.8% 10.6% 12.6% 9.1% 8.7% 8.4% 8.9% 7.2% 9.8% 13.4%
Operating margin 7.5% 6.3% 3.7% 3.6% 9.7% 8.9% 7.7% 7.4% 7.0% 6.9% 6.1% −5.9% −4.4% −4.6% −3.8% −36.8% −50.0% −45.1%
Net margin 4.5% 3.0% 0.7% −1.6% 4.2% 8.5% 4.9% 4.0% 7.8% 6.4% −15.9% 3.8% 5.0% −0.9% −1.9% −39.2% −52.7% −48.0%
Free-cash-flow margin 5.3% 9.1% 6.1% 2.3% 6.9% 6.5% 6.8% 5.8% 7.7% 7.1% 0.2% 16.7% 17.7% −10.3% 0.7% −3.2% 0.9% 2.8%
Cash flow
Cash from operations 39 62 57 174 362 386 304 247 219 226 131 302 356 −56 135 114 217 270
Capital spending 11 13 15 84 71 84 70 63 69 70 125 115 104 105 122 181 197 206
Free cash flow 28 49 42 90 291 301 234 184 150 157 6 187 252 −161 13 −67 20 64
Stock-based pay 3 3 5 9 13 18 16 19 22 25 22 29 35 39 34 30 33 35
Free cash flow after stock pay 25 46 37 81 277 284 218 165 128 132 −16 158 217 −200 −21 −97 −13 29
Balance sheet
Cash 50 61 75 482 311 305 197 209 262 77 110 97 680 24 36 48 36 13
Total debt — — 112 1,784 1,505 1,552 1,426 1,298 1,070 1,205 2,329 2,247 2,094 259 480 1,343 1,308 1,285
Net debt (negative = net cash) −50 −61 36 1,301 1,193 1,246 1,229 1,089 808 1,128 2,220 2,150 1,414 235 444 1,295 1,272 1,272
Diluted shares — 29m 30m 30m 33m 41m 42m 41m 41m 40m 46m 46m 51m 54m 54m 55m 57m 57m
Returned to shareholders
Dividends — 0 0 0 — — — — — — — — — — — — — —
Buybacks — — — — 0 0 27 21 0 200 0 0 — 0 0 5 4 —
Total returned — 0 0 0 0 0 27 21 0 200 0 0 — 0 0 5 4 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · July 3, 2026
What it owns · $3.8bn
Short-term assets $1.2bnLonger-term assets $2.6bn
What it owes, and who funded it · $3.8bn
Short-term liabilities $612mLonger-term liabilities $1.7bnShareholders' equity $1.5bn
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $612m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $1.7bn of longer-dated liabilities.
  • More cash than debt $13m of cash against $1.3bn of debt.
  • Debt below 40% of shareholders' equity Debt is 87% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 45% to 87% over five years.
  • A year's operating cash flow covers at least 20% of debt $270m of operating cash flow against $1.3bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$1.0bn against $34m of interest.

From Enovis Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$8.3M
Diluted share count
+1.7%
year over year
R&D spending
5.4%
of revenue
Sales & admin spending
47.1%
of revenue
Days sales outstanding
70 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated ENOV TFX QDEL ITGR RVTY PODD Median
Revenue, last 12 months $2.3bn $2.3bn $2.7bn $1.8bn $2.9bn $3.1bn $99m
Revenue growth, last 12 months 4.9% 30.7% −2.5% −0.3% 4.1% 29.4% 9.2%
Revenue growth, 3-year average 12.2% −8.0% −5.4% 6.7% 0.9% 27.7% 13.5%
Revenue growth, latest quarter 3.2% 28.9% 2.8% −3.9% 1.3% 23.5% 10.2%
Gross margin 61.1% 54.9% — 24.6% 60.1% 71.1% 61.2%
Operating margin −45.1% 2.0% −30.8% 8.2% 12.3% 16.9% −8.5%
Operating margin, 3-year average −28.5% 5.7% −34.4% 10.7% 12.0% 16.2% −17.9%
Net margin −48.0% −45.8% −39.2% 5.7% 8.2% 12.3% −12.0%
Cash from operations / revenue 11.8% 10.8% −2.1% 9.7% 21.6% 16.7% −1.9%
Free-cash-flow margin 2.8% 7.5% −7.9% 4.5% 19.2% 9.0% −3.9%
Free-cash-flow margin, 3-year average −0.2% 7.7% −4.5% 5.2% 17.1% 11.6% −7.0%
Stock pay / revenue 1.5% 1.1% 1.7% 1.3% 0.3% 2.6% 6.1%
Change in share count 1.7% −4.0% 0.9% −0.8% −6.2% −3.6% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 4.9% 9.1% 85 of 129
Change in growth rate Growth -1.1pp -0.6pp 75 of 129
Gross margin Profitability 61.1% 61.9% 65 of 123
Operating margin Profitability -45.1% -8.3% 88 of 132
Net margin Profitability -48.0% -12.0% 87 of 133
Free-cash-flow margin Cash generation 2.8% -3.4% 46 of 128
Stock pay as % of revenue Cash generation 1.5% 6.1% 22 of 123
Long-term debt as % of assets Balance sheet 33.1% 24.2% 62 of 87
Change in share count Balance sheet 1.7% 3.3% 44 of 115
Days sales outstanding Balance sheet 70 days 57 days 84 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Prevention and Recovery $1.1B 50.6% ▲ 3.6%
Reconstructive $1.1B 49.4% ▲ 10.0%
Geography
Region Revenue Share YoY
United States $1.3B 57.6% ▲ 4.0%
Foreign $953M 42.4% ▲ 10.5%

From Enovis Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.5B
Institutions reporting
250
Shares held vs prior quarter
▲ 4.9%
Positions opened / closed
39 / 44

Top buyers and sellers, Q2 2026: 127 institutions bought and 132 sold ; the biggest buyer was Rubric Capital Management LP (+1.4M shares) and the biggest seller Dimensional Fund Advisors LP (−801K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $213M 10.3M 14.6% ▲ 3.6%
American Century Companies Inc $126M 6.1M 8.7% ▲ 28.0%
Vanguard Portfolio Management LLC $81.3M 3.9M 5.6% ▲ 3.1%
Rubric Capital Management LP $80.7M 3.9M 5.5% ▲ 59.0%
Vanguard Capital Management LLC $51.4M 2.5M 3.5% ▼ 2.7%
State Street Corp $51M 2.5M 3.5% ▲ 2.5%
Davenport & Co LLC $48.5M 2.3M 3.3% ▼ 4.0%
Hood River Capital Management LLC $47.6M 2.3M 3.3% ▲ 30.9%
FMR LLC $45.7M 2.2M 3.1% ▲ 62.1%
Goldman Sachs Group Inc $36.7M 1.8M 2.5% ▲ 13.0%
Dimensional Fund Advisors LP $36.1M 1.7M 2.5% ▼ 31.5%
Geode Capital Management, LLC $31M 1.5M 2.1% ▲ 9.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Enovis Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $762,432 18 trades by 3 insiders, last 12 months Insider sales History → $45,298 4 trades by 1 insider · 0% under pre-set plans
Net ▲ $717,134 net buying
Insider Date Trade Shares Price Value
Mcdonald Damien Chief Executive Officer September 4, 2026 Buy 13,035 $19.15 $249,620
Engert Oliver Chief Administrative Officer September 4, 2026 Buy 2,660 $18.80 $50,008
Engert Oliver Chief Administrative Officer September 3, 2026 Buy 5,140 $19.46 $100,024
Engert Oliver Chief Administrative Officer September 2, 2026 Buy 2,458 $20.32 $49,947
Engert Oliver Chief Administrative Officer June 15, 2026 Buy 1,000 $20.92 $20,920
Engert Oliver Chief Administrative Officer June 11, 2026 Buy 200 $20.99 $4,198
Engert Oliver Chief Administrative Officer June 11, 2026 Buy 1,000 $21.75 $21,750
Engert Oliver Chief Administrative Officer June 10, 2026 Buy 1,000 $23.00 $23,000
Engert Oliver Chief Administrative Officer June 1, 2026 Buy 1,000 $22.22 $22,220
Engert Oliver Chief Administrative Officer March 13, 2026 Buy 1,000 $23.74 $23,740
Engert Oliver Chief Administrative Officer March 10, 2026 Buy 1,000 $23.93 $23,930
Engert Oliver Chief Administrative Officer March 9, 2026 Buy 1,000 $23.39 $23,390

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Enovis Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Enovis Corp in brief

What does Enovis Corp do?
Enovis Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Enovis Corp's stock ticker?
Enovis Corp trades under the ticker ENOV on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Enovis Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Enovis Corp reported revenue of $2.3B, 4.9% higher than a year earlier, according to its SEC filings.
What is Enovis Corp's free cash flow?
Enovis Corp's free-cash-flow margin is 2.8% of revenue over the trailing twelve months, ranking 46 of the 128 health care equipment companies we cover.
Who are Enovis Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., American Century Companies Inc and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Enovis Corp's market cap?
On November 2, 2026, Enovis Corp's market capitalisation was about $1.2B and net debt of $1.3B. Market figures come from third-party market data and may be delayed.
How much debt does Enovis Corp have?
Enovis Corp's debt-to-equity ratio is 87.0%, from its latest balance sheet (45.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Enovis Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Enovis Corp are Teleflex Inc, Quidelortho Corp, Integer Holdings Corp, Revvity and Insulet Corporation. The side-by-side comparison below sets their revenue, margins and growth against Enovis Corp's.
Are insiders buying or selling Enovis Corp stock?
Over the last 12 months, Enovis Corp's directors and officers reported 18 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Enovis Corp's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Enovis Corp announces its own schedule.